Preclinical Immunological Evaluation of an Intradermally Administered Heterologous Vaccine Against SARS-CoV-2 Variants
Qihan Li(Changchun University of Technology), Wenbo Xu(Shenyang Institute of Automation), Penglan Chang(Academy of Medical Sciences), Kang Xiao(Chinese Center For Disease Control and Prevention), Baicheng Xia(Chinese Academy of Medical Sciences & Peking Union Medical College), Yang Song(National Institute for Viral Disease Control and Prevention), Bangyi Zheng(Academy of Medical Sciences), Fengyuan Zeng(Academy of Medical Sciences), Guorun Jiang(Chinese Academy of Medical Sciences & Peking Union Medical College), Yun Liao(Apple (Israel)), Xingli Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Shengtao Fan, Suqin Duan(Academy of Medical Sciences), Tianjiao Ji(National Health and Family Planning Commission), Xiaolei Li(National Institute for Viral Disease Control and Prevention), Jingjing Zhang(Nanjing University), Dandan Li(Fujian Medical University), Lichun Wang(Academy of Medical Sciences), Yu Li(Academy of Medical Sciences), Zhanlong He(Chinese Academy of Medical Sciences & Peking Union Medical College), Heng Zhao(Shandong Tumor Hospital), Ying Zhang(Second Affiliated Hospital of Guangzhou Medical University), Pingfang Cui(Academy of Medicine), Shuangli Zhu(Chinese Center For Disease Control and Prevention), Yaxing Zhang(Chinese Academy of Sciences), Dongmei Yan(Chinese Center For Disease Control and Prevention), Fengmei Yang(Jiangsu University)
Cited by 0
Related Papers
A Novel Coronavirus from Patients with Pneumonia in China, 2019
|New England Journal of Medicine|2020|30.5k
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
|The Lancet|2020|12.6k
The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice
|Nature|2020|1.2k